Condition
Idiopathic Multicentric Castleman's Disease
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Unknown3
Terminated1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05995834UnknownPrimary
Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS)
NCT04838860Phase 2TerminatedPrimary
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
NCT04743687Phase 2UnknownPrimary
Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial
NCT03982771Phase 2UnknownPrimary
BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)
Showing all 4 trials